Stifel Nicolaus Issues Positive Forecast for Heartflow (NASDAQ:HTFL) Stock Price

Heartflow (NASDAQ:HTFL) had its price objective boosted by equities researchers at Stifel Nicolaus from $35.00 to $40.00 in a research note issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ price objective suggests a potential upside of 29.83% from the company’s current price.

Other analysts also recently issued reports about the stock. Wall Street Zen raised shares of Heartflow to a “hold” rating in a research note on Saturday, August 16th. Piper Sandler began coverage on Heartflow in a research report on Tuesday, September 2nd. They set an “overweight” rating and a $38.00 price target on the stock. Weiss Ratings started coverage on Heartflow in a research report on Saturday, November 1st. They set a “sell (d+)” rating for the company. JPMorgan Chase & Co. started coverage on Heartflow in a report on Tuesday, September 2nd. They issued an “overweight” rating and a $36.00 target price on the stock. Finally, Zacks Research raised shares of Heartflow to a “hold” rating in a research note on Wednesday, September 3rd. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $37.60.

Heartflow Trading Down 13.8%

NASDAQ HTFL traded down $4.93 on Thursday, hitting $30.81. 632,081 shares of the company were exchanged, compared to its average volume of 410,884. Heartflow has a twelve month low of $26.56 and a twelve month high of $41.22. The company’s 50 day moving average price is $34.73.

Heartflow (NASDAQ:HTFL) last announced its earnings results on Friday, September 19th. The company reported ($1.46) EPS for the quarter, missing the consensus estimate of ($0.20) by ($1.26). The business had revenue of $43.42 million for the quarter, compared to the consensus estimate of $43.20 million.

Hedge Funds Weigh In On Heartflow

A number of institutional investors have recently modified their holdings of the company. Baillie Gifford & Co. bought a new stake in shares of Heartflow during the 3rd quarter worth $101,182,000. Vanguard Group Inc. bought a new stake in Heartflow during the third quarter valued at about $48,871,000. Capital International Investors acquired a new stake in shares of Heartflow in the third quarter valued at about $43,671,000. Artisan Partners Limited Partnership bought a new position in shares of Heartflow in the third quarter worth about $16,817,000. Finally, JPMorgan Chase & Co. acquired a new position in shares of Heartflow during the 3rd quarter worth about $13,887,000.

Heartflow Company Profile

We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of March 31, 2025, our Heartflow Platform has been used to assess CAD in more than 400,000 patients, including 132,000 in 2024 alone.